- Home
- AGEN
AGEN
Agenus Inc.
as 10-29-2025 4:00pm EST
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 123.6M | IPO Year: | 2000 |
| Target Price: | $14.50 | AVG Volume (30 days): | 470.9K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.38 - $7.34 | Next Earning Date: | 11-11-2025 |
| Revenue: | $101,706,000 | Revenue Growth: | -36.29% |
| Revenue Growth (this year): | 60.49% | Revenue Growth (next year): | -19.74% |
Latest Agenus Inc. News
AGEN Breaking Stock News: Dive into AGEN Ticker-Specific Updates for Smart Investing
Business Wire
13 days ago
Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025
Business Wire
14 days ago
Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights
Zacks
4 months ago
Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag
Zacks
4 months ago
FDA Grants Label Expansion to AstraZeneca's Datroway in Lung Cancer
Zacks
4 months ago
After Golden Cross, Agenus (AGEN)'s Technical Outlook is Bright
MT Newswires
4 months ago
Agenus Partners With Noetik to Advance Biomarker Discovery for Lead Cancer Immunotherapy Combo
Business Wire
4 months ago
Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology
Insider Monkey
4 months ago
Agenus Inc. (AGEN) Surges After Zydus Agreement, Analysts Upbeat on Stock
Compare AGEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AGEN Agenus Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.